|
Press Room
2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
January 29, 2008
Three Leading Pharmaceutical Trade Publications Highlight InNexus’ Proprietary Technology, Dynamic Cross Linking. Coverage Includes Drug Delivery Technology, Innovations in Pharmaceutical Technology, and PFQ Magazine
BRITISH COLUMBIA, Canada—29 January 2008—-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), was recently featured in three leading pharmaceutical publications, Drug Delivery Technology, Innovations in Pharmaceutical Technology, and PFQ Magazine. This media exposure is part of an aggressive public relations initiative to elevate awareness of the Company’s proprietary technology, world-class team and pharmaceutical industry partners.
In an effort to garner interest among the pharmaceutical community, including research and development professionals, CEO Jeff Morhet contributed an article to Drug Delivery Technology’s Specialty Pharma section. The piece describes InNexus’ Dynamic Cross Linking technology and how it could be used to improve the target-binding affinity of existing monoclonal antibodies (MoAbs) as well as those in development. The full text of the article (total circulation: 20,000) titled “Improving Therapeutic Antibodies” noted how Dynamic Cross Linking (DXL), under development at InNexus Biotechnology, improves an antibody’s avidity for its target without affecting critical binding or immunogenicity factors. DXL is based on the discovery that certain naturally occurring antibodies bind to one another, as dimers, after they attach to a target.
InNexus CEO Jeff Morhet also contributed a bylined story to Innovations in Pharmaceutical Technology, a unique publication based in the United Kingdom dedicated to the analysis and discovery of new ideas, developments, and innovations affecting the research and production of finished pharmaceuticals. Mr. Morhet was among a select number of leading authorities and experts within the pharmaceutical and biotech industries asked to identify the next generation of innovations that will soon be making a tremendous impact. Mr. Morhet’s story focuses on DXL technology. The journal is distributed worldwide three times a year to over ten thousand industry professionals and is a supporting partner to many leading pharmaceutical conferences, exhibitions, and other events. The current issue can be viewed on a complimentary basis with a free sign in.
Finally, Mr. Morhet also bylined an article that was also featured in a recent issue of PFQ Magazine (total circulation: 16,500). Addressing research and development scientists, senior management, and outsourcing decision makers, Mr. Morhet discussed the challenges that lay ahead for MoAbs. In the article, Mr. Morhet states that, “The fact that DXL MoAbs are entirely new molecules is both a blessing and a curse of sorts. The good news is that, being entirely new molecules, these products carry no intellectual property restrictions. Since InNexus owns the relevant patents, the entire portfolio of current MoAb blockbusters is open to DXL modification. The bad news is that since these are new compositions of matter, regulatory authorities and good clinical practice suggests each one must be tested as such, through a complete set of clinical trials.”
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
InNexus Biotechnology Inc.
480-862-7500
Media:
Janet Vasquez/ Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
|
|
|
